BACKGROUND: A light-porous-particle, dry-powder formulation of tobramycin was developed, using PulmoSphere® technology, to improve airway delivery efficiency, substantially reduce delivery time, and improve patient convenience and satisfaction. We evaluated the safety, efficacy and convenience of tobramycin inhalation powder (TIP™) versus tobramycin inhalation solution (TIS, TOBI®) for treating Pseudomonas aeruginosa infection in cystic fibrosis (CF) patients aged ≥6 years. METHODS: In this open-label study, 553 patients were randomized 3:2 to TIP (total 112mg tobramycin) via the Novartis T-326 Inhaler or TIS 300mg/5mL via PARI LC® PLUS nebulizer twice daily for three treatment cycles (28 days on-drug, 28 days off-drug). Safety, efficacy, and treatment satisfaction outcomes were evaluated. RESULTS: TIP was generally well-tolerated; adverse events were similar in both groups. The rate of cough suspected to be study drug related was higher in TIP-treated patients (TIP: 25.3%; TIS: 4.3%), as was the overall discontinuation rate (TIP: 26.9%; TIS: 18.2%). Increases in FEV(1)% predicted from baseline to Day 28 of Cycle 3 were similar between groups; the mean reduction in sputum P. aeruginosa density (log(10) CFU/g) on Day 28 of Cycle 3 was also comparable between groups. Administration time was significantly less for TIP (mean: 5.6 versus 19.7min, p<0.0001). Treatment satisfaction was significantly higher for TIP for effectiveness, convenience, and global satisfaction. CONCLUSIONS: TIP has a safety and efficacy profile comparable with TIS, and offers a far more convenient treatment option for pseudomonas lung infection in CF. Copyright Â
RCT Entities:
BACKGROUND: A light-porous-particle, dry-powder formulation of tobramycin was developed, using PulmoSphere® technology, to improve airway delivery efficiency, substantially reduce delivery time, and improve patient convenience and satisfaction. We evaluated the safety, efficacy and convenience of tobramycin inhalation powder (TIP™) versus tobramycin inhalation solution (TIS, TOBI®) for treating Pseudomonasaeruginosa infection in cystic fibrosis (CF) patients aged ≥6 years. METHODS: In this open-label study, 553 patients were randomized 3:2 to TIP (total 112mg tobramycin) via the Novartis T-326 Inhaler or TIS 300mg/5mL via PARI LC® PLUS nebulizer twice daily for three treatment cycles (28 days on-drug, 28 days off-drug). Safety, efficacy, and treatment satisfaction outcomes were evaluated. RESULTS: TIP was generally well-tolerated; adverse events were similar in both groups. The rate of cough suspected to be study drug related was higher in TIP-treated patients (TIP: 25.3%; TIS: 4.3%), as was the overall discontinuation rate (TIP: 26.9%; TIS: 18.2%). Increases in FEV(1)% predicted from baseline to Day 28 of Cycle 3 were similar between groups; the mean reduction in sputum P. aeruginosa density (log(10) CFU/g) on Day 28 of Cycle 3 was also comparable between groups. Administration time was significantly less for TIP (mean: 5.6 versus 19.7min, p<0.0001). Treatment satisfaction was significantly higher for TIP for effectiveness, convenience, and global satisfaction. CONCLUSIONS: TIP has a safety and efficacy profile comparable with TIS, and offers a far more convenient treatment option for pseudomonaslung infection in CF. Copyright Â
Authors: Timothy D Murphy; Ran D Anbar; Lucille A Lester; Samya Z Nasr; Bruce Nickerson; Donald R VanDevanter; Andrew A Colin Journal: Pediatr Pulmonol Date: 2004-10
Authors: H A Tiddens; D E Geller; P Challoner; R J Speirs; K C Kesser; S E Overbeek; D Humble; S B Shrewsbury; T A Standaert Journal: J Aerosol Med Date: 2006
Authors: Michael T Newhouse; Peter H Hirst; Sarma P Duddu; Yulia H Walter; Thomas E Tarara; Andrew R Clark; Jeffry G Weers Journal: Chest Date: 2003-07 Impact factor: 9.410
Authors: B W Ramsey; M S Pepe; J M Quan; K L Otto; A B Montgomery; J Williams-Warren; M Vasiljev-K; D Borowitz; C M Bowman; B C Marshall; S Marshall; A L Smith Journal: N Engl J Med Date: 1999-01-07 Impact factor: 91.245
Authors: Mark J Atkinson; Anusha Sinha; Steven L Hass; Shoshana S Colman; Ritesh N Kumar; Meryl Brod; Clayton R Rowland Journal: Health Qual Life Outcomes Date: 2004-02-26 Impact factor: 3.186
Authors: Olanrewaju O Okusanya; Sujata M Bhavnani; Jeffrey P Hammel; Alan Forrest; Catharine C Bulik; Paul G Ambrose; Renu Gupta Journal: Antimicrob Agents Chemother Date: 2014-03-31 Impact factor: 5.191
Authors: N Mayer-Hamblett; S van Koningsbruggen-Rietschel; D P Nichols; D R VanDevanter; J C Davies; T Lee; A G Durmowicz; F Ratjen; M W Konstan; K Pearson; S C Bell; J P Clancy; J L Taylor-Cousar; K De Boeck; S H Donaldson; D G Downey; P A Flume; P Drevinek; C H Goss; I Fajac; A S Magaret; B S Quon; S M Singleton; J M VanDalfsen; G Z Retsch-Bogart Journal: J Cyst Fibros Date: 2020-06-07 Impact factor: 5.482
Authors: Rachel Yoon Kyung Chang; Philip Chi Lip Kwok; Sussan Ghassabian; John D Brannan; Heikki O Koskela; Hak-Kim Chan Journal: Br J Pharmacol Date: 2020-08-07 Impact factor: 8.739
Authors: Qianru Yu; Edward F Griffin; Sophie Moreau-Marquis; Joseph D Schwartzman; Bruce A Stanton; George A O'Toole Journal: J Antimicrob Chemother Date: 2012-07-26 Impact factor: 5.790